Inventiva (IVA) Cash from Operations (2019 - 2025)
Inventiva (IVA) recorded quarterly Cash from Operations of 60814534.24 in Q2 2025, down 16.82% quarter-over-quarter from 52058899.21 in Q2 2024, and down 16.82% on a YoY basis from 73110832.82 in Q2 2024.
Inventiva (IVA) Cash from Operations (2019 - 2025) Analysis & Trends
Inventiva's Cash from Operations history runs 6 years deep, the most recent figure standing at 60814534.24 for Q2 2025.
- In Q2 2025, Cash from Operations fell 16.82% year-over-year to 60814534.24; the TTM figure through Jun 2025 stood at 166985369.46 (down 29.63% YoY), while the FY2025 annual figure was 122089540.0, down 32.96% from the prior year.
- Cash from Operations was 60814534.24 for Q2 2025 at Inventiva, down from 52058899.21 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 9385723.18 in Q1 2021 to a low of 60814534.24 in Q2 2025.
- Historically, Cash from Operations has averaged 30496724.28 across 4 years, with a median of 26751906.17 in 2022.
- The sharpest annual moves came in 2021 and 2025: Cash from Operations plunged 265.59% in 2021, then declined 16.82% in 2025.
- A 4-year view of Cash from Operations shows it stood at 22641473.06 in 2021, then fell by 18.15% to 26751906.17 in 2022, then plunged by 94.6% to 52058899.21 in 2024, then dropped by 16.82% to 60814534.24 in 2025.
- The last three Cash from Operations figures came in at 60814534.24 (Q2 2025), 52058899.21 (Q2 2024), and 26751906.17 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Inventiva | 8.93 Mn | -259.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -60.81 Mn |
| Jun 30, 2025 | -60.81 Mn |
| Jun 30, 2024 | -52.06 Mn |
| Jun 30, 2024 | -52.06 Mn |
| Dec 31, 2022 | -26.75 Mn |
| Dec 31, 2022 | -26.75 Mn |
| Sep 22, 2022 | -27.36 Mn |
| Sep 22, 2022 | -27.36 Mn |
| Dec 31, 2021 | -22.64 Mn |
| Dec 31, 2021 | -22.64 Mn |
| Jun 30, 2021 | -14.46 Mn |
| Jun 30, 2021 | -14.46 Mn |
| Mar 31, 2021 | -9.39 Mn |
| Mar 31, 2021 | -9.39 Mn |
| Dec 31, 2020 | -8.55 Mn |
| Dec 31, 2020 | -8.55 Mn |
| Jun 30, 2020 | -3.96 Mn |
| Jun 30, 2020 | -3.96 Mn |
| Mar 31, 2020 | -3.95 Mn |
| Mar 31, 2020 | -3.95 Mn |